JFS Wealth Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

JFS Wealth Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-64	Closed	-$5K	–	1880
2022 Q2	$5K	Buy	+64	New	+$5K	﹤0.01%	1004

Other funds holding PPH

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LJAC

L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return

JFS Wealth Advisors's PPH Position: Q3 2022 in Review

JFS Wealth Advisors sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2022, closing a stake of 64 shares — an estimated $5K sold.

JFS Wealth Advisors first reported a position in PPH in Q2 2022 and held it in 1 quarter. The position peaked at $5K in Q2 2022. 86 funds tracked by Wall St. Rank hold PPH as of Q3 2022.

JFS Wealth Advisors reported no remaining VanEck Pharmaceutical ETF position as of Q3 2022 after selling out during the quarter.
JFS Wealth Advisors sold 64 VanEck Pharmaceutical ETF shares in Q3 2022, an estimated $5K.
JFS Wealth Advisors first reported a position in VanEck Pharmaceutical ETF in Q2 2022 and held it in 1 quarter.
JFS Wealth Advisors's VanEck Pharmaceutical ETF position peaked at $5K in Q2 2022.
86 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2022.

Based on JFS Wealth Advisors's 13F filing for Q3 2022, filed 21 Oct 2022.